COYA - Coya Therapeutics Year-over-year net earnings per share growth for the last 12 months

Coya Therapeutics, Inc. (COYA) is developing a closed Treg-therapy ecosystem to combat neurodegeneration. On the GURU.Markets platform, the volatility of the quarterly EPS illustrates profit dynamics, where the figure stands at -258.40. The business scales easily on a global level due to its ownership of intellectual property. The innovative pipeline focuses on creating breakthrough treatments for Alzheimer's and ALS.
coyatherapeutics.com (COYA) - metric breakdowns and financial figures

For the biotech sector, where Treg therapy development costs are high, earnings per share (EPS) dynamics reflect capital management efficiency within a closed patent perimeter. Analyzing quarterly EPS volatility allows for the exclusion of one-time financial anomalies, revealing the actual net income growth rate and confirming the fundamental asset value stability of Coya Therapeutics, Inc. (COYA) across various market cycles.